



## นพ.สรวิศ โอสถาปนธ์

ผู้ได้รับพระราชทานทุนโครงการเยาวชนรางวัลสมเด็จพระเจ้าพี่นางเธอ ประจำปี 2558 (รุ่นที่ 7)

**โครงการ:** Modulating hyperglycemic memory using epigenetic: Future direction of diabetic vasculopathy research

**อาจารย์ที่ปรึกษา:** รศ. พญ.สมลักษณ์ จึงสมาน และ ผศ. ดร.วัลยา ทัศนพงศ์ธรรม

**International Mentor:** Assoc. Prof. Mary-Elizabeth-Patti

### Publication and presentation:

#### ● Publication

1. **Osataphan S**, Patell R, Chiasakul T, Khorana A, Zwicker J. Extended thromboprophylaxis for medically-ill patients with cancer: a systemic review and meta-analysis, *Blood Adv* (2021) 5 (8): 2055–2062.
2. **Osataphan S**, Augustynowicz, A, Perrino C, Lam P. Triple-hit high grade B-cell lymphoma presenting with ovarian torsion. *BMJ Case Rep*. 2021 May 31; 14(5): e242423.
3. **Osataphan S**, Mahankasuwan T, Saengboonmee C. Obesity and Cholangiocarcinoma: A review of Epidemiological and Molecular Associations. *J Hepatobiliary Pancreat Sci*. 2021 May 30.
4. Kozuka C, Sales VS, **Osataphan S**, Yuchi Y, Chimene-Weiss J, Mulla C, Isganaitis E, Desmond J, Sanechika S, Kusuyama J, Goodyear LJ, Shi X, Gerszten RE, Wu L, Qi J, Patti ME. Bromodomain inhibition reveals FGF15/19 as a target of epigenetic regulation and metabolic control, *bioRxiv* 2019.12.11.872887; doi: <https://doi.org/10.1101/2019.12.11.872887>
5. **Osataphan S**, Patti ME. Trim the gut, lose the weight - and the bone. *J Clin Invest*. 2019; 129(7): 2184-6.
6. **Osataphan S**, Macchi C, Singhal G, Chimene-Weiss J, Sales V, Kozuka C, et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. *JCI Insight*. 2019 Mar 7; 4(5). pii: 123130.
7. Chenbhanich J, Atsawarungruangkit A, Korpaisarn S, Phupitakphol T, **Osataphan S**, Phowthongkum P. Prevalence of thyroid diseases in familial adenomatous polyposis: A systematic review and meta-analysis. *Fam Cancer*. 2019; 18(1): 53-62.



8. **Osataphan S**, Chalermchai T, Ngaosuwan K. Clinical inertia causing new or progression of diabetic retinopathy in type 2 diabetes: A retrospective cohort study. *J Diabetes*. 2017; 9(3): 267-74.
9. Ngaosuwan K, **Osataphan S**. Diabetes mellitus treated with medical nutritional therapy and self blood glucose monitoring: A randomized controlled trial. *J Med Assoc Thai*. 2015; 98 Suppl 10: S66-73.

- **Oral presentation**

1. **Osataphan S**. The SGLT-2 inhibitor Canagliflozin requires FGF21 to reduce adiposity in nondiabetic mice with dietary obesity. Oral presentation presented at: Ethan Sims Award Session/Obesity Week; Nashville, TN, USA. (Ethan Sims Young Investigator Award 2018 Finalist), November, 2018
2. **Osataphan S**. SGLT2 Inhibition reduces paternal intergenerational transmission of metabolic disease in mice with dietary obesity. Oral presentation presented at: The United States Society of Developmental Origins of Health and Disease. Chapel Hill, NC, USA. (Trainee award 2018), October, 2018

- **Poster presentation**

1. **Osataphan S**, Jan YJ, Stafford KA, Lam PB. Effect of excess weight on immune-related adverse events from immune checkpoint inhibitor in lung cancer. Abstract presented at: American Society of Clinical Oncology; Chicago, IL, USA. June, 2021
2. Efthymiou V, Chimene-Weiss J, Zhou L, **Osataphan S**, Su L, Patti ME. CTCFL Is a Fasting-Induced Epigenetic Regulator That Modulates Lipid and Cholesterol Metabolism in the Liver. Poster presented at: American Diabetes Association; Virtual meeting, June, 2021.
3. Su L, **Osataphan S**, Desmond J, Fang R, Chimene-Weiss J, et al. The SGLT2 inhibitor Paternal Obesity and SGLT2 Inhibition Alter Expression of Placental Regulatory Genes. Poster presented at: Endocrine Society 2021; Virtual Meeting. March, 2021.